Although we did not have sufficient numbers of patients with post-treatment samples to attempt to analyze sex-related differences, we did observe, as previously reported in lung cancer patients (16), a significant increase in CXCL10 in non-responders while on-treatment, as well as a near-significant increase in IL-6. This evidence concerns the gene CXCL10 and lung cancer.